arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

EXICURE, INC.

XCUR
$1.28 ▲ +0.05 (+4.07%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
41 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

EXICURE, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $8.2M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -107.9%
FCF / Share $-0.14
Trailing P/E
Price / Book 8.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

41-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-1.83M
— 0.0%
Operating Margin Operating profit as % of sales
-167.2%
↓ -295.8%
FCF / Share Free cash flow per share
$-0.14
↑ +22.3%
Long-Term Debt Long-term obligations
$16.80M
— +0.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
6
Cash Quality
83

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 11 years · 41 quarters